A landmark meta-analysis published in PLOS Medicine has provided compelling evidence that Molecular Tumor Boards (MTBs) represent a significant advancement in personalized cancer treatment. Researchers analyzing data from 78 studies involving 9,195 cancer patients found that MTB-guided therapies reduce death risk by 13% and disease progression by 27% compared to standard care protocols.
The study, conducted by Dr. Luigi Russo and colleagues at the Catholic University of the Sacred Heart, demonstrates that precision medicine approaches—which translate genomic profiling into clinical decisions—deliver measurable improvements across multiple outcome measures. These findings underscore the growing importance of multidisciplinary expert collaboration in oncology, where tailored genetic insights guide treatment selection for individual patients.
Read the full article on GMJ Newsroom.
Was this article helpful?
